Enterovirus A vaccine - Medigen Vaccinology/Adimmune

Drug Profile

Enterovirus A vaccine - Medigen Vaccinology/Adimmune

Alternative Names: EV-71 vaccine; EV71 vaccine inactivated - Medigen; Inactive whole monovalent EV71 virion vaccine

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Health Research Institutes
  • Developer Adimmune Corporation; Medigen Vaccinology Corp; National Health Research Institutes
  • Class Enterovirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Enterovirus A infections

Most Recent Events

  • 08 Aug 2017 Medigen Biotechnology plans a phase III trial for enterovirus A vaccine
  • 01 Aug 2017 Medigen Vaccine Biologics Corp completes a phase II trial in Enterovirus A infections (In volunteers, In infants, In children, Prevention) in Taiwan (Parenteral) (NCT02200237)
  • 28 Jul 2017 Taiwan's Ministry of Health and Welfare approves phase III trial for enterovirus A vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top